⌘K
Loading ticker…
As of 2026-08-24, 10x Genomics, Inc. Class A Common Stock (TXG) has a 3-month relative strength percentile of 99 and a leadership percentile of 99 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 98. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.1%, relative volume 1.20×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
TXG is in a stage 2 uptrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 40.3% / 138.0%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
TXG appears in 1 ETF as of Jun 2026: PSC at 0.41% weight, $9M notional.
Held by 89 ETFs · $726M across latest filings · largest weight 5.77% (ARKG).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.41% | $9M | +0.14 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | TXG Jan avg: 7.82% median: 14.15% win: 75% σ: 24.56% n: 4 2022-04-12 → 2026-07-31 | TXG Feb avg: -0.31% median: 6.70% win: 75% σ: 19.74% n: 4 2022-04-12 → 2026-07-31 | TXG Mar avg: -7.09% median: -13.11% win: 25% σ: 17.14% n: 4 2022-04-12 → 2026-07-31 | TXG Apr avg: -12.72% median: -6.02% win: 20% σ: 15.18% n: 5 2022-04-12 → 2026-07-31 | TXG May avg: 5.48% median: 7.18% win: 80% σ: 19.28% n: 5 2022-04-12 → 2026-07-31 | TXG Jun avg: 7.71% median: 6.44% win: 60% σ: 21.06% n: 5 2022-04-12 → 2026-07-31 | TXG Jul avg: 9.45% median: 12.79% win: 80% σ: 13.11% n: 5 2022-04-12 → 2026-07-31 | TXG Aug avg: -4.59% median: -6.75% win: 50% σ: 15.61% n: 4 2022-04-12 → 2026-07-31 (current) | TXG Sep avg: -13.49% median: -15.12% win: 0% σ: 7.34% n: 4 2022-04-12 → 2026-07-31 | TXG Oct avg: -7.84% median: -9.52% win: 25% σ: 19.18% n: 4 2022-04-12 → 2026-07-31 | TXG Nov avg: 25.67% median: 30.63% win: 75% σ: 19.41% n: 4 2022-04-12 → 2026-07-31 | TXG Dec avg: -0.03% median: -7.71% win: 25% σ: 19.33% n: 4 2022-04-12 → 2026-07-31 |